Breaking News

Oxford Biomedical Awarded NIH Grant

By Kristin Brooks | December 10, 2013

To develop proteomic toxicity screening panel

Oxford Biomedical Research, Inc. has been awarded a Phase II Small Business Innovation Research Grant by the National Institute of Environmental Health Sciences. The grant, valued at $1.2 million, is for the development of a panel of tests designed to use GST proteins as more sensitive and specific biomarkers to detect toxicity and differentiate potential toxic effects to multiple organs.
 
GST proteins, found in many tissues and organs, play an important role in the elimination of drugs and environmental compounds that humans are exposed to and are considered extremely sensitive biomarkers for toxicity.
 
Researchers at Oxford Biomedical Research have already assembled tests for a number of GST proteins. The NIH-funded research includes development of a device that can rapidly and inexpensively measure multiple GSTs. The utility of GSTs for organ-specific toxicity testing will be validated by comparison to conventional toxicity tests used during drug development and in the clinic.
blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Heavy Metals in Drug Products

    Heavy Metals in Drug Products

    Nikki Schopp, Team Leader in charge of ICP-MS, ICP-OES and AA testing, SGS||January 29, 2015
    The potential presence of trace amounts of heavy metals in drug products is a real cause for concern with regulators.

  • Microbiological Testing & Contamination Control

    Microbiological Testing & Contamination Control

    Daniel L. Prince, Ph. D., Christopher J. Waskewich, M.S., Kristah J. Kohan, B.S. and Danina G. Rinaldi, B.S. , Gibraltar Laboratories, Inc.||March 7, 2014
    An opinion on the microbial limit test with reference to harmonization.